Research

LIke ThisLIke ThisLIke This

Stephan  Voss, MD, PhD

Stephan Voss, MD, PhD
Department:
Radiology Research
Division
Hospital Title:
Director, Nuclear Medicine and Molecular Imaging; Division Chief, Oncologic Imaging
Academic Title:
Associate Professor of Radiology, Harvard Medical School
Research Focus Area:
Neuroblastoma imaging
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Stephan Voss' principal research interest is in developing novel tools to more specifically image malignant disease. The goal of his work, using neuroblastoma both as a laboratory research and clinical model, is to develop neuroblastoma-specific imaging tools that permit pediatric radiologists to image the childhood malignancy with greater sensitivity and specificity. He is the chair of the Imaging section for the multi-center, NCI-sponsored Children's Oncology Group Phase I Consortium.

Research in the Voss laboratory is aimed at developing an animal model for neuroblastoma that can be readily imaged using either a small bore animal magnet, or small animal nuclear medicine cameras.

Voss and colleagues are developing and testing targeted contrast agents, using single chain antibodies derived from intact antibodies with reactivity against neuroblastoma. The single chain antibody (sFv) work involves a team of investigators directed at creating NB- specific, high sensitivity contrast agents by covalently conjugating small tumor targeting antibody fragments (sFv) to nuclear medicine agents, which include both conventional SPECT agents such as 99mTc and novel PET agents such as 64Cu.

In addition to these basic research pursuits, Voss' group is working pediatric oncologists to develop a more systematic assessment of the optimal imaging strategy for diagnosis and follow-up imaging in children with various cancers.

About Stephan Voss

Stephan Voss received his MD degree from the University of Wisconsin. He completed an internship at New England Deconess Hospital, a residency at Beth Israel Deaconess Medical Center and a fellowship at Boston Children's Hospital.

Publications

Publications powered by Harvard Catalyst Profiles
  1. O'Neill AF, Adil EA, Irace AL, Neff L, Davis IJ, Perez-Atayde AR, Voss SD, Weinberg O, Rahbar R. Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management. Int J Pediatr Otorhinolaryngol. 2016 Jul; 86:218-23.
  2. Madenci AL, Levine BS, Laufer MR, Boyd TK, Voss SD, Frazier AL, Weldon CB. Poor adherence to staging guidelines for children with malignant ovarian tumors. J Pediatr Surg. 2016 Sep; 51(9):1513-7.
  3. Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51.
  4. Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43.
  5. Gauguet JM, Prabhu SP, Pigula F, Voss SD. The radiographic appearance of split Blake drains: what you see is not necessarily what you get. Pediatr Radiol. 2013 Dec; 43(12):1573-6.
  6. Nehra D, Fallon EM, Potemkin AK, Voss SD, Mitchell PD, Valim C, Belfort MB, Bellinger DC, Duggan C, Gura KM, Puder M. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug; 38(6):693-701.
  7. Croteau SE, Henderson ER, Billett AL, Gebhardt MC, Voss SD. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer. 2013 Oct; 60(10):E113-5.
  8. Ramon-Krauel M, Salsberg SL, Ebbeling CB, Voss SD, Mulkern RV, Apura MM, Cooke EA, Sarao K, Jonas MM, Ludwig DS. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013 Jun; 9(3):252-60.
  9. Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80.
  10. Freiman M, Perez-Rossello JM, Callahan MJ, Voss SD, Ecklund K, Mulkern RV, Warfield SK. Reliable estimation of incoherent motion parametric maps from diffusion-weighted MRI using fusion bootstrap moves. Med Image Anal. 2013 Apr; 17(3):325-36.
  11. Show all
  12. Freiman M, Voss SD, Mulkern RV, Perez-Rossello JM, Callahan MJ, Warfield SK. In vivo assessment of optimal b-value range for perfusion-insensitive apparent diffusion coefficient imaging. Med Phys. 2012 Aug; 39(8):4832-9.
  13. Freiman M, Voss SD, Mulkern RV, Perez-Rossello JM, Callahan MJ, Warfield SK. Reliable assessment of perfusivity and diffusivity from diffusion imaging of the body. Med Image Comput Comput Assist Interv. 2012; 15(Pt 1):1-9.
  14. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62.
  15. Jakacki RI, Bouffet E, Adamson PC, Pollack IF, Ingle AM, Voss SD, Blaney SM. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro Oncol. 2011 Aug; 13(8):910-5.
  16. Guillerman RP, Voss SD, Parker BR. Leukemia and lymphoma. Radiol Clin North Am. 2011 Jul; 49(4):767-97, vii.
  17. Klein JD, Turner CG, Gray FL, Yu DC, Kozakewich HP, Perez-Atayde AR, Voss SD, Zurakowski D, Shamberger RC, Weldon CB. Adrenal cortical tumors in children: factors associated with poor outcome. J Pediatr Surg. 2011 Jun; 46(6):1201-7.
  18. Voss SD. Pediatric oncology and the future of oncological imaging. Pediatr Radiol. 2011 May; 41 Suppl 1:S172-85.
  19. Freiman M, Voss SD, Mulkern RV, Perez-Rossello JM, Warfield SK. Quantitative body DW-MRI biomarkers uncertainty estimation using unscented wild-bootstrap. Med Image Comput Comput Assist Interv. 2011; 14(Pt 2):74-81.
  20. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75.
  21. Bixby SD, Hettmer S, Taylor GA, Voss SD. Synovial sarcoma in children: imaging features and common benign mimics. AJR Am J Roentgenol. 2010 Oct; 195(4):1026-32.
  22. Taylor GA, Voss SD, Melvin PR, Graham DA. Diagnostic errors in pediatric radiology. Pediatr Radiol. 2011 Mar; 41(3):327-34.
  23. Yu DC, Grabowski MJ, Kozakewich HP, Perez-Atayde AR, Voss SD, Shamberger RC, Weldon CB. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg. 2010 Jun; 45(6):1090-5.
  24. Wang LL, Filippi RZ, Zurakowski D, Archibald T, Vargas SO, Voss SD, Shamberger RC, Davies K, Kozakewich H, Perez-Atayde AR. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol. 2010 Mar; 34(3):287-99.
  25. Voss SD, Reaman GH, Kaste SC, Slovis TL. The ALARA concept in pediatric oncology. Pediatr Radiol. 2009 Nov; 39(11):1142-6.
  26. Mulkern RV, Salsberg SL, Krauel MR, Ludwig DS, Voss S. A paradoxical signal intensity increase in fatty livers using opposed-phase gradient echo imaging with fat-suppression pulses. Pediatr Radiol. 2008 Oct; 38(10):1099-104.
  27. Blackman SC, Evenson AR, Voss SD, Barnewolt CE, Puder M. Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther. 2008; 24(2):119-25.
  28. Mulkern RV, Hung YP, Ababneh Z, Maier SE, Packard AB, Uluer MC, Kacher DF, Gambarota G, Voss S. On the strong field dependence and nonlinear response to gadolinium contrast agent of proton transverse relaxation rates in dairy cream. Magn Reson Imaging. 2005 Jul; 23(6):757-64.
  29. Alwayn IP, Gura K, Nosé V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar; 57(3):445-52.
  30. Voss SD, DeGrand AM, Romeo GR, Cantley LC, Frangioni JV. An integrated vector system for cellular studies of phage display-derived peptides. Anal Biochem. 2002 Sep 15; 308(2):364-72.
  31. Voss SD, Kruskal JB, Kane RA. Chronic inflammatory pseudotumor arising in the hepatobiliary-pancreatic system: progressive multisystemic organ involvement in four patients. AJR Am J Roentgenol. 1999 Oct; 173(4):1049-54.
  32. Voss SD, Kruskal JB. Gene therapy: a primer for radiologists. Radiographics. 1998 Nov-Dec; 18(6):1343-72.
  33. Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, Patel AT, Robertson MJ, Nadler LM, Freeman GJ. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998 Sep 15; 161(6):2780-90.
  34. Voss SD, Daley J, Ritz J, Robertson MJ. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998 Feb 15; 160(4):1618-26.
  35. Ida H, Robertson MJ, Voss S, Ritz J, Anderson P. CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells. J Immunol. 1997 Sep 1; 159(5):2154-60.
  36. Robertson MJ, Cameron C, Lazo S, Cochran KJ, Voss SD, Ritz J. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996-1997; 15(5):213-26.
  37. Farner NL, Voss SD, Leary TP, Gan J, Hakimi J, Evans G, Ju G, Sondel PM. Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood. 1995 Dec 15; 86(12):4568-78.
  38. Farner NL, Voss SD, Sondel PM. X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Clin Diagn Lab Immunol. 1995 Sep; 2(5):518-23.
  39. Sondel PM, Voss SD, Hong R. Addendum to SCID, interleukin-2, and the interleukin-2 receptor review. Blood. 1994 Jul 15; 84(2):667-8.
  40. Voss SD, Hong R, Sondel PM. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood. 1994 Feb 1; 83(3):626-35.
  41. Voss SD, Leary TP, Sondel PM, Robb RJ. Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1993 Mar 15; 90(6):2428-32.
  42. Kaur I, Voss SD, Gupta RS, Schell K, Fisch P, Sondel PM. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. J Immunol. 1993 Mar 1; 150(5):2046-55.
  43. Voss SD, Sondel PM, Robb RJ. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med. 1992 Aug 1; 176(2):531-41.
  44. Bogner MP, Voss SD, Bechhofer R, Hank JA, Roper M, Poplack D, Hammond D, Sondel PM. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb; 11(2):111-8.
  45. Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med. 1990 Oct 1; 172(4):1101-14.
  46. Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res. 1990 May 1; 50(9):2683-91.
  47. Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother. 1989; 29(4):261-9.
  48. Voss SD, Weil-Hillman G, Hank JA, Sosman JA, Sondel PM. The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. Bull N Y Acad Med. 1989 Jan; 65(1):93-110.
  49. Drubach LA, Voss SD, Kourmouzi V, Connolly LP. The ischiopubic synchondrosis: changing appearance on PET/CT as a mimic of disease. Clin Nucl Med. 2006 Jul; 31(7):414-7.
  50. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7.
  51. Voss SD, Murphey MD, Hall FM. Solitary osteosclerotic plasmacytoma: association with demyelinating polyneuropathy and amyloid deposition. Skeletal Radiol. 2001 Sep; 30(9):527-9.
  52. Lee EY, Vargas SO, Sawicki GS, Boyer D, Grant FD, Voss SD. Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol. 2007 Dec; 37(12):1278-82.
  53. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7.
  54. Cua CL, Sanghavi D, Voss S, Laussen PC, del Nido P, Marshall A, Breitbart RE. Right ventricular pseudoaneurysm after modified Norwood procedure. Ann Thorac Surg. 2004 Oct; 78(4):e72-3.
  55. Voss SD, Smith SV, DiBartolo N, McIntosh LJ, Cyr EM, Bonab AA, Dearling JL, Carter EA, Fischman AJ, Treves ST, Gillies SD, Sargeson AM, Huston JS, Packard AB. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A. 2007 Oct 30; 104(44):17489-93.
  56. Lee EY, Dillon JE, Callahan MJ, Voss SD. 3D multidetector CT angiographic evaluation of extralobar pulmonary sequestration with anomalous venous drainage into the left internal mammary vein in a paediatric patient. Br J Radiol. 2006 Sep; 79(945):e99-102.
  57. Yu DC, Voss SD, Javid PJ, Jennings RW, Weldon CB. In utero diagnosis of congenital pyloric atresia in a single twin using MRI and ultrasound. J Pediatr Surg. 2009 Nov; 44(11):e21-4.
  58. Rothstein DH, Voss SD, Isakoff M, Puder M. Thymoma in a child: case report and review of the literature. Pediatr Surg Int. 2005 Jul; 21(7):548-51.
  59. Voss SD, Chen L, Constine LS, Chauvenet A, Fitzgerald TJ, Kaste SC, Slovis T, Schwartz CL. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20; 30(21):2635-40.
  60. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13.
  61. Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, Huston JS, Meares CF, Treves ST, Packard AB. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011 Jan; 38(1):29-38.
  62. Voss SD. Surveillance imaging in pediatric Hodgkin Lymphoma. Curr Hematol Malig Rep. 2013 Sep; 8(3):218-25.
  63. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6.
  64. Dearling JL, Paterson BM, Akurathi V, Betanzos-Lara S, Treves ST, Voss SD, White JM, Huston JS, Smith SV, Donnelly PS, Packard AB. The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution. Bioconjug Chem. 2015 Apr 15; 26(4):707-17.
  65. Ly S, Frates MC, Benson CB, Peters HE, Grant FD, Drubach LA, Voss SD, Feldman HA, Smith JR, Barletta J, Hollowell M, Cibas ES, Moore FD, Modi B, Shamberger RC, Huang SA. Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center. J Clin Endocrinol Metab. 2016 Oct; 101(10):3856-3862.
  66. Schwartz CL, Chen L, McCarten K, Wolden S, Constine LS, Hutchison RE, de Alarcon PA, Keller FG, Kelly KM, Trippet TA, Voss SD, Friedman DL. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatr Blood Cancer. 2016 Oct 27.
LIke ThisLIke ThisLIke This
Close